OpenAI ignites the AI medical track, UNISOUND (09678) value reassessment window has arrived.

Recently, OpenAI officially launched ChatGPT Health and OpenAI for Healthcare, exclusive products for the medical field. This move, like a stone thrown into the industry lake, has sparked strong interest from the global capital market. From now on, the AI medical field has moved from being "ready to go" to "accelerating forward," and the leading domestic company UNISOUND (09678), which has been strategically positioned for years, is seizing a historical opportunity for value reassessment with its technological barriers, commercial achievements, and policy support. Explosive growth in the race: a dual drive of policy and market, AI medical becomes a new investment blue ocean The popularity of AI medical is not accidental but rather the inevitable result of the convergence of mature technology, policy support, and market demand. OpenAI's entry into the medical field not only validates the huge commercial potential of the track but also accelerates the industry's transition from technological concepts to essential application. On the data front, the track is growing rapidly. By 2024, the global AI medical market size has reached $26.65 billion, expected to soar to $505.59 billion by 2033, with a high compound annual growth rate of 38.8% during the period. The Chinese market is the most promising growth pole globally, with policy support injecting strong momentum. In November 2025, the National Health Commission and five other departments jointly issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Medical Health'" clearly stating the goal of establishing an AI medical application system by 2027 and achieving deep integration by 2030, focusing on supporting the landing of AI in primary care, hospital intelligence, and other core scenarios. Driven by both policy and market demand, the Chinese AI medical market is expected to reach 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% between 2023 and 2033, becoming one of the most certain investment blue oceans. "Shanhai" model builds barriers, authoritative certification demonstrates hard strength Among the many participants in the track, UNISOUND's first-mover advantage and technological accumulation are particularly outstanding. As early as 2016, when most AI companies were focusing on consumer internet, UNISOUND foresaw the future by entering the field of "smart healthcare," becoming one of the few domestic companies with long-term deep medical AI. In December 2025, the company launched the medical expert Large-scale model "Shanhai-Zhiyi Large Model 5.0," marking a key leap from "assistive response" to "active cooperation" in its medical AI technology system. The model builds a technological barrier with a dual-core architecture of "medical text large model + medical multimodal large model," addressing four clinical pain points: integrating full-stack capabilities covering text processing, intelligent body collaboration, and other core needs, providing "one-stop" diagnostic support; advanced reasoning abilities to simulate clinical thinking, achieving the evolution from "cognitive brain" to "actor"; multimodal technology accurately identifying image lesions, completing cross-modal semantic alignment and joint reasoning; training on massive and high-quality medical data, leading the industry in information extraction accuracy, and ensuring medical safety by controlling medical illusions through advanced training paradigms. Technological strength is certified by authority. In the December 2025 Shanghai Artificial Intelligence Research Institute MedBench 4.0 evaluation, the "Shanhai-Zhiyi Large Model 5.0" won the first place in three categories: medical intelligence body, medical large language model, and medical multimodal large model, outperforming top international models and becoming the industry's only "triple crown," fully verifying its technological leadership. Commercial breakthrough: 400 hospitals vote with real money, UNISOUND's value awakening in progress Unlike many companies that remain in the technological concept stage, UNISOUND has efficiently transformed technology into commercialization, establishing a complete closed loop of "technology-product-revenue." Currently, the smart healthcare product matrix has been deployed nationwide, solutions have been implemented in nearly 400 hospitals, with more than 700 in the testing phase, covering hundreds of top-tier hospitals, continuous growth of user base and market penetration rate. In specific application scenarios, the product's value is fully demonstrated: the outpatient medical record generation system at the Friendship Hospital has a direct reference rate of nearly 90%, significantly reducing the burden of medical documentation; the DRG/DIP medical insurance payment management system has helped large insurance institutions complete the deployment of a national nuclear insurance claim risk control platform, improving the efficiency and risk control capabilities of medical insurance funds, and achieving significant clinical and operational benefits. Large-scale deployment translates into strong revenue growth. In 2024, UNISOUND's overall revenue increased by 29.1% year-on-year, with medical business revenue growing by 34.4%, becoming the core growth engine. Guotai Haitong's research report pointed out that as a pioneer in the industrialization of Chinese AGI technology, UNISOUND's technological barriers and commercialization capabilities have not been fully priced, giving an initial "increase" rating and a target price of 451.33 Hong Kong dollars, expecting revenue to maintain a high-speed growth of over 35% in 2025-2027. Value reassessment: Rare leader meets opportunity, long-term potential to be unleashed Currently, the AI medical track is on the eve of the concentrated release of policy dividends and the explosive commercialization and scale. OpenAI's entry opens up industry imagination space, while policy enhancements provide solid guarantees. For investors, the real opportunity lies in exploring companies that can solve clinical pain points and achieve large-scale implementation. UNISOUND, with its technological barriers in first-mover advantage, authoritative certified product strength, nationwide customer matrix, and growing revenue, occupies a scarce top position in the high certainty track. However, the current valuation has not fully reflected its true value and growth potential. As the "Shanhai-Zhiyi Large Model 5.0" iterates and upgrades, expands landing scenarios, and releases policy dividends, UNISOUND's commercialization process will accelerate comprehensively. Standing at the critical juncture of the scale and popularization of AI medical, this "hidden champion" that has been deeply cultivating the industry for many years is entering a historical window of systematic value reassessment. Its undervalued long-term value is expected to continue to stand out in the wave of track explosions, becoming a high-quality target for investors to layout the AI medical track.